Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Avalo Therapeutics (AVTX) Equity Average (2016 - 2025)

Avalo Therapeutics (AVTX) has disclosed Equity Average for 11 consecutive years, with $98.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Equity Average rose 2526.15% year-over-year to $98.1 million, compared with a TTM value of $98.1 million through Sep 2025, up 2526.15%, and an annual FY2024 reading of $70.2 million, up 3986.35% over the prior year.
  • Equity Average was $98.1 million for Q3 2025 at Avalo Therapeutics, down from $113.6 million in the prior quarter.
  • Across five years, Equity Average topped out at $127.8 million in Q1 2025 and bottomed at -$63.1 million in Q2 2024.
  • Average Equity Average over 5 years is $22.5 million, with a median of $11.0 million recorded in 2023.
  • The sharpest move saw Equity Average tumbled 3485.17% in 2023, then skyrocketed 2526.15% in 2025.
  • Year by year, Equity Average stood at $31.7 million in 2021, then crashed by 120.42% to -$6.5 million in 2022, then surged by 269.97% to $11.0 million in 2023, then soared by 600.52% to $77.1 million in 2024, then increased by 27.26% to $98.1 million in 2025.
  • Business Quant data shows Equity Average for AVTX at $98.1 million in Q3 2025, $113.6 million in Q2 2025, and $127.8 million in Q1 2025.